Loading data for ABCL — first visit, this takes a few seconds.

Alerta

AbCellera Biologics Inc. (ABCL)

NasdaqGS: ABCL · Precio en tiempo real · USD

11.12

-0.08 (-0.71%)

Al cierre: Aug 18, 2026, 8:00 PM

11.09

-0.27%

Premercado: 8:06 AM

-0.71% (1D)

No hay datos disponibles

Precio de compra	8.28
Capitalización de mercado	3.41B
Ingresos (TTM)	66.17M
Beneficio neto (TTM)	-164.66M
Beta	1.19
EPS (TTM)	-0.54
Ratio PER (TTM)	n/a
Adelante PE	-15.55
P/B (TTM)	3.80
P/S (TTM)	51.53
Earnings Date	Nov 5, 2026

Precio de venta	13.73
Volumen	8,169,847
Volumen medio (20D)	8,141,037
Abierto	10.90
Anterior Cerrar	11.20
Rango del día	10.70 - 11.52
Rango de 52 semanas	2.75 - 11.64
analista	n/a
Precio objetivo	n/a
Dividendos	n/a
Fecha ex dividendo	n/a

Acerca de ABCL

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, su...

[Leer más]

Industria Biotechnology

Sector Healthcare

IPO Fecha Dec 11, 2020

Empleados 562

Bolsa de Valores NasdaqGS

Símbolo bursátil ABCL

Sitio web https://www.abcellera.com

Perfil completo de la empresa

Desempeño financiero

En 2025, los ingresos de AbCellera Biologics fueron 75.13M, un aumento de 160.56% en comparación con 28.83M del año anterior. Las ganancias fueron -146.41M, una disminución de -10.1%.

Estados financieros

Sorpresa de resultados

AbCellera Biologics ha publicado sus resultados trimestrales en Aug 5, 2026:

Ingresos de $4.05M falla las estimaciones por $0, con -76.29% Disminución interanual.

EPS de -0.18 falla las estimaciones por -0.02, con -50.00% Disminución interanual.

Próxima publicación de resultados

Está previsto que AbCellera Biologics Inc. publique sus resultados el Nov 5, 2026, durante el horario de mercado.
Los analistas proyectan ingresos de ... Actualizar

Noticias

3 días hace · Insider Monkey

AbCellera (ABCL) Soars 64% as Drug Candidate Holds Huge Market Opportunity

AbCellera Biologics (NASDAQ:ABCL) has seen its stock price jump by 64 percent week-on-week, making it the top-performing mid-cap stock in the US market last week, thanks to strong clinical trial resul...

4 días hace · Insider Monkey

Can AbCellera Biologics (ABCL)’s Vertex Pharmaceuticals Incorporated (VRTX) Deal Turn its TCE Platform Into a Breakthrough?

On July 29, AbCellera Biologics Inc. (NASDAQ:ABCL) and Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) announced a strategic collaboration to research, develop, and commercialize multispecific T-cel...

5 días hace · MT Newswires

Exchange-Traded Funds, Equity Futures Higher Pre-Bell Thursday Amid Producer Inflation Data Release

The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was up 0.2%, and the actively tra

6 días hace · Motley Fool

AbCellera (ABCL) Q2 2026 Earnings Call Transcript

Lead program ABCL635 Phase 2 enrollment complete with data expected in August.

1 semana hace · Simply Wall St.

AbCellera Biologics (ABCL) Is Up 60.3% After Strong Phase 2 Menopause Data For ABCL635 - Has The Bull Case Changed?

AbCellera Biologics recently reported that its investigational antibody ABCL635 achieved statistically significant Phase 2 results, with a single 600 mg subcutaneous dose reducing both the frequency a...

Página 1 de 2

AbCellera Biologics Inc. (ABCL)